Clinical characteristics of pediatric myasthenia: A surveillance study

Pediatrics

Volumn 132, Issue 4, 2013, Pages

  VanderPluym, Juliana ^a   Vajsar, Jiri ^b   Jacob, Francois Dominique ^a   Mah, Jean K ^c   Grenier, Danielle ^d   Kolski, Hanna ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d Canadian Hypertension Society   (Canada)

Author keywords

Congenital myasthenic syndromes; Incidence; Myasthenia gravis

Indexed keywords

CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN; PYRIDOSTIGMINE; STEROID;

ADOLESCENT; ARTICLE; CANADA; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG RESPONSE; ELECTROMYOGRAPHY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NERVE STIMULATION; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; PTOSIS; SCHOOL CHILD; TREND STUDY;

EID: 84885122343     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-0814     Document Type: Article

References (31)

1. Erb W. Zur Casuistik der bulbaren Lahmungen. 3 Ueber einen neuen, wahrscheinlich bulbaren Symptomencomplex. Arch Psychiatr Nervenkr. 1879;9:336-350
2. Phillips LH II, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42(10):1888-1893
3. Zhang X, Yang M, Xu J, et al. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry. 2007;78(4):386-390
4. Rodriguez M, Gomez MR, Howard FM Jr, Taylor WF. Myasthenia gravis in children: long-term follow-up. Ann Neurol. 1983;13 (5):504-510
5. Kimura K, Nezu A, Kimura S, et al. A case of myasthenia gravis in childhood associated with chronic inflammatory demyelinating polyradiculoneuropathy. Neuropediatrics. 1998;29(2):108-112
6. Papazian O. Transient neonatal myasthenia gravis. J Child Neurol. 1992;7(2):135-141
7. Harper CM. Congenital myasthenic syndromes. Semin Neurol. 2004;24(1):111-123
8. Statistics Canada. (2012). Table 051-0001: estimates of population, by age group and sex for July 1, Canada, provinces and territories. http://www5.statcan.gc.ca/cansim/pick-choisir?lang5eng&p2533&id=0510001
9. McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010;34(3):171-183
10. Zivadinov R, Jurjevic A, Willheim K, Cazzato G, Zorzon M. Incidence and prevalence of myasthenia gravis in the county of the coast and Gorski kotar, Croatia, 1976 through 1996. Neuroepidemiology. 1998;17(5):265-272
11. Matuja WB, Aris EA, Gabone J, Mgaya EM. Incidence and characteristics of Myasthenia gravis in Dar Es Salaam, Tanzania. East Afr Med J. 2001;78(9):473-476
12. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797-1810
13. Andrews PI. Autoimmune myasthenia gravis in childhood. Semin Neurol. 2004;24(1): 101-110
14. Andrews PI, Massey JM, Howard JF Jr, Sanders DB. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology. 1994; 44(7):1208-1214
15. Andrews PI, Massey JM, Sanders DB. Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology. 1993;43(5): 977-982
16. Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve. 2009;39 (4):423-431
17. Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis. 2011;2011:404101
18. McMillan HJ, Darras BT, Kang PB. Autoimmune neuromuscular disorders in childhood. Curr Treat Options Neurol. 2011;13 (6):590-607
19. Parr JR, Jayawant S. Childhood myasthenia: clinical subtypes and practical management. Dev Med Child Neurol. 2007;49(8): 629-635
20. Deymeer F, Gungor-Tuncer O, Yilmaz V, et al. Clinical comparison of anti-MuSK-vs anti-AChR-positive and seronegative myasthenia gravis. Neurology. 2007;68(8):609-611
21. Takahashi Y, Sugiyama M, Ueda Y, et al. Childhood-onset anti-MuSK antibody positive myasthenia gravis demonstrates a distinct clinical course. Brain Dev. 2012;34(9): 784-786
22. Sri-udomkajorn S, Panichai P, Liumsuwan S. Childhood myasthenia gravis: clinical features and outcomes. J Med Assoc Thai. 2011;94 (Suppl 3):S152-S157
23. Ashraf VV, Taly AB, Veerendrakumar M, Rao S. Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand. 2006;114(2): 119-123
24. Kim JH, Hwang JM, Hwang YS, Kim KJ, Chae J. Childhood ocular myasthenia gravis. Ophthalmology. 2003;110(7):1458-1462
25. Lindner A, Schalke B, Toyka KV. Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients. J Neurol. 1997;244(8):515-520
26. Melbourne Chambers R, Forrester S, Gray R, Tapper J, Trotman H. Myasthenia gravis in Jamaican children: a 12-year institutional review. Paediatr Int Child Health. 2012;32(1):47-50
27. Yang ZX, Xiong H, Zhang YH, et al. [Clinical characteristics and follow-up management of 135 children with myasthenia gravis]. Beijing Da Xue Xue Bao. 2011;43 (3):455-459
28. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980;103(3):579-601
29. Toth C, McDonald D, Oger J, Brownell K. Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta Neurol Scand. 2006;114(2):124-132
30. Evoli A, Batocchi AP, Bartoccioni E, Lino MM, Minisci C, Tonali P. Juvenile myasthenia gravis with prepubertal onset. Neuromuscul Disord. 1998;8(8):561-567
31. Statistics Canada. (2012). Population by year, by province and territory. http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo02a-eng.htm